March 20, 2018 / 11:54 AM / 6 months ago

BUZZ-Trillium Therapeutics: Up after CTCL drug gets 'orphan' status

** U.S.-listed shares of drug developer up 2.6 pct at $8 premarket

** U.S. FDA grants orphan drug status to TTI-621 for treating cutaneous T-cell lymphoma, a class of non-Hodgkin lymphoma, which is type of cancer of immune system.

** Stock up 8 pct this year, after gaining 28 pct in 2017 (Reporting by Amy Caren Daniel in Bengaluru)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below